Sepracor Inc. on Friday disclosed that Johnson & Johnson has elected not to exercise its option to co-promote SEPR's norastemizole non-sedating antihistamine to treat seasonal and perennial allergic rhinitis. But SEPR contended that the news will not meaningfully alter its burn rate or force the company to slow any programs. Additionally, norastemizole may now be partnered with other potential suitors.

SEPR Senior Vice President and CFO David Southwell told BioCentury